{"id":"W3151557472","doi":"10.1016/j.cgh.2021.04.006","title":"Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn’s Disease","year":2021,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"Takeda Canada; MedImmune; Diagnostic Services Manitoba; AbbVie Canada; Seres Therapeutics; Nippon Kayaku; Boehringer Ingelheim; Janssen Pharmaceuticals; Gilead Sciences; Yale University; Roche; Teva Pharmaceutical Industries; Ferring Pharmaceuticals; Novartis; Pfizer; Shire; Eli Lilly and Company; Schering-Plough; Abbott Laboratories","keywords":"Medicine; Ustekinumab; Infliximab; Internal medicine; Post-hoc analysis; Calprotectin; Crohn's disease; Odds ratio; Randomized controlled trial; Gastroenterology; Inflammatory bowel disease; Disease","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002783538,0.0004453922,0.002523559,0.0005637054,0.0001997263,0.0009350201,0.0003770988,0.001040243,0.002299913],"category_scores_gemma":[0.004508275,0.0002827351,0.001435359,0.0003624726,0.0006995234,0.001259913,0.0002888859,0.001675423,0.0003712253],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004894998,"about_ca_system_score_gemma":0.0003371178,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003682665,"about_ca_topic_score_gemma":0.0005510718,"domain_scores_codex":[0.9986907,0.000729594,0.0001265436,0.0001175176,0.0001302326,0.0002054099],"domain_scores_gemma":[0.9958233,0.002695625,0.0005041821,0.0003023724,0.0001307107,0.0005439103],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9229083,0.002029758,0.007478451,0.0004333625,0.0009551197,0.0002176506,0.000143132,0.000928666,0.01392664,0.0002355767,0.0002136954,0.0505297],"study_design_scores_gemma":[0.1674115,0.6532316,0.1522866,0.0001817329,0.00540602,0.0008377765,0.0003538619,0.002677904,0.01365579,0.0007923962,0.003056911,0.0001080518],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879383,0.01001038,0.0001498162,0.0001874,0.000142976,0.00004347278,0.0001457179,0.00001605831,0.001365916],"genre_scores_gemma":[0.9978217,0.001172195,0.0001530592,0.00009054967,0.0001692259,0.00002903051,0.0001668053,0.000005652154,0.0003918438],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002783538,"threshold_uncertainty_score":0.01472092,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06485969466783972,"score_gpt":0.3721182119531091,"score_spread":0.3072585172852694,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}